PharmTech Drug Digest 11.20
News|Articles|March 28, 2014

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-04-02-2014
  • Volume 10
  • Issue 4

AmerisourceBergen Acquires Minority Interest in Profarma

Author(s)Melanie Sena

AmerisourceBergen to establish a joint venture for specialty distribution with Profarma.

AmerisourceBergen

reported that it has reached a definitive agreement to acquire a minority stake in Profarma, a pharmaceutical wholesaler in Brazil. In addition, AmerisourceBergen and Profarma will establish a joint venture for specialty distribution and services. The company expects to invest a total of approximately $100 million, and the transaction is expected to close in the June quarter of 2014.

AmerisourceBergen will purchase up to a 19.9% minority stake by offering $22.50 per share for shares offered in a primary offering by Profarma. This distribution joint venture will include Profarma’s existing specialty businesses and an equity investment from AmerisourceBergen. As a result, each company will own a 50% stake in the joint venture.

Source:

AmerisourceBergen


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.